J&J Covid vaccine shows 85% effectiveness in reducing Omicron hospitalisation

The data have been submitted to the pre-print server medRxiv by the studies’ authors, with anticipation of publication in peer-reviewed journals.Data from the Sisonke 2 trial, which included 227,310 healthcare workers in South Africa who received the single-shot Johnson & Johnson Covid-19 vaccine as a primary dose, show that the Johnson & Johnson Covid-19 booster increased vaccine effectiveness (VE) against hospitalization to 85 per cent.When a booster shot was administered six to nine months after a primary single dose, VE increased over time from 63 per cent at 0-13 days, to 84 per cent at 14-27 days and 85 per cent at 1-2 months post-boost.Sisonke 2 was conducted in approximately 350 vaccination centres across all nine provinces of South Africa.Utilising data from a South African managed care organisation, trial investigators determined VE of the Johnson & Johnson Covid-19 booster shot (ni,092) as compared to other individuals enrolled in the same managed care organisation, during the period from November 15, 2021, through December 20, 2021.



Source link